Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope

Now Viewing

EP: 1.Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope

EP: 2.Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial

EP: 3.Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study

EP: 4.Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety

EP: 5.Cross Q&A: Managing Cardiovascular Risks in CML Treatment

EP: 6.Asciminib in CML Treatment: Efficacy and Responses Shown in the ASCEMBL Study

EP: 7.Cross Q&A: Evaluating Ponatinib and Asciminib as 3L Therapy in CML

EP: 8.Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy

EP: 9.Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

Transcript:

Judy Schreiber, PhD, RN: Hi, good morning and welcome to Cancer Network’s Face-Off. Today we’re going to focus on multiple myeloma and chronic myeloid leukemia. My name is Judy Schreiber, and I’m the program host today. A little bit about the program. Face-Off is a series that’s a little different than many of the educational programs that you’re used to.… Make no mistake, it’s educational at its core, but it’s also designed to be fun. So, what makes Face-Off different from other educational events is the fact that it’s not just a presentation, but it’s more than that. It’s a competition. So, here in Pasadena, [California,] we have the visiting team online from the University of Washington Fred Hutchinson Cancer Center captained by Dr Vivian Oehler, and the home team from City of Hope captained by Dr Paul Koller. And they’re not just presenting data to you, but they’re presenting it [to] each other.

The visiting team will lead off. Visiting teams always go first, and they will be presenting several studies to the home team, after which, the home team will have the opportunity to challenge the visiting team. Presenters should make sure that their presentation contains certain levels of enthusiasm. And at the end of each Q&A session, they’ll appear on your screen for the fans. That’s you in the audience. If you have any questions…or comments you want to make, you’re free to also make those comments. We have a number of attendees here in Pasadena. And then…at the end of the multiple myeloma section, then also at the end of the CML section, we’re going to have a couple of questions. And [we’ll use] the answers to the questions…to score how each team did. So the team with the most correct answers will go home the winners. Trophies, ribbons, and bragging rights forever. Not only that, but Cancer Network is donating a starting amount of $2000 to your institution’s fellows’ travel fund for participating in this program. And for the team that wins, they get an additional $1000 for their fellows’ travel fund. So cheer your colleagues on. And at this time, I would like Dr Oehler first to introduce herself and her team. And when she’s done, we’ll follow up with Dr Kohler introducing his team here.

Vivian G. Oehler, MD: So, good morning, everyone. [I thought] Dr Cowan…was our fearless leader. But Dr Andrew Cowan is going to be our myeloma person. And Dr Rahul Banerjee is also with us today. And I’m Vivian Oehler, and we’re all from the Fred [Hutchinson Cancer Center]. Good morning, everyone. I’m going to say you all look very serious.

Judy Schreiber, PhD, RN: Is that better?

Paul B. Koller, MD: My turn. So, my name is Paul Koller. I’m from City of Hope. I will be talking about CML [chronic myeloid leukemia]. And then we have Dr Lawrence Liu, who’s one of our fellows at City of Hope, who will be giving us some information on myeloma. And Dr Murali Janakiram, who will also be talking about myeloma. And we’re excited to participate in this. And I think the seriousness was because I was not expecting to talk at all right now.

Murali Janakiram, MD, MS: We just thought it was a win and we can go home.

Transcript is AI-generated and edited for clarity and readability.